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L E T T E R  T O  T H E  E D I T O R
Unraveling the complexity of atopic dermatitis: The CK-CARE 
approach toward precision medicine
To the editor,
Although clinicians acknowledge the phenotypic heterogeneity of 
atopic dermatitis (AD), its current management remains a “one-size-
fits-all” approach. Even the newest approved medicinal products and 
those in the pipeline ground on the assumption of a single or domi-
nant underlying mechanism which are mainly based on two pillars: (a) 
intrinsically disturbed epidermal barrier function as the result of nu-
merous candidate genes related to the biochemical structure of the 
epidermis such as Filaggrin-1 or 2, Claudin-1, and many others; (b) 
the assumed dominant T2 type of immune response locally mainly 
involving IL-13 and IL-31.
Recent reports exploring the immunologic background unrav-
eled different immune responses in various ethnic populations1 
and between pediatric and adult patients.2 We begin to understand 
the mechanisms behind the complexity of AD. Substantial hurdles 
in translating this emerging knowledge into personalized preven-
tion and therapeutic strategies toward precision medicine remain.3 
Overcoming these hurdles is a major task for academic research 
which has access to large and representative cohorts. In this letter, 
(a) we expose the gaps in our understanding of the complexity of AD 
and (b) describe the approach chosen by the Christine Kühne-Allergy 
Research and Education (CK-CARE) program.
Critical questions need to be addressed in systematic approaches 
to improve our understanding of the complexity of AD:
• Is the epidermal barrier dysfunction or rather the disturbed im-
mune response more relevant for triggering the first lesions in 
infancy, childhood or adults?
• The mechanisms underlying the various AD onsets remain elu-
sive.4 Did the patients with late onset (=adult onset) or very late 
onset (older than 60 years) have AD in infancy/childhood? The 
concept of AD as a “dormant disease,” that is, individuals who re-
ported to have had AD in childhood or adulthood and in whom the 
disease has not shown any sign of activity for more than 10 years, 
needs to be explored.
• The functional genomics beyond dry and sensitive skin remains 
mysterious. The consequences for the trans-epidermal IgE-
sensitization need to be addressed.
• The role of visible and subclinical inflammation and their systemic 
impact remain an unsolved issue.
• The mechanisms leading to “atopic march” and nonatopic comor-
bidities are enigmatic.5
• Staphylococcus aureus-dominated skin dysbiosis has been inves-
tigated in sophisticated studies, but the chicken or egg question 
remains. Does the dysbiosis play a role in infancy while being an 
epiphenomenon later on?6
• The role of IL-4 and IL-13 is assumed to be essential.7 More recent 
findings point to a sequence of mechanisms also involving IL-17 
and IL-22. This impacts on the development of innovative thera-
pies targeting pivotal structures with biologics, small molecules, 
or protein-protein interaction modulators (PPIMs).
• The adaptive immunity undergoes an initial “learning phase” in 
infancy/early childhood offering a window of opportunity for in-
tervention. It is unclear which children would benefit from this 
strategy to prevent AD and stop the “atopic march.”
• The role of IgE and the concept of extrinsic/intrinsic AD remain 
elusive. Should we revise this dogma based on an arbitrary defini-
tion of total serum IgE levels?
• SCORAD, EASI, and vIGA-AD are validated tools and mandatory 
for regulatory purposes, but the thresholds for severity grades are 
arbitrary. What is the scientific rationale for the current definition 
of mild, moderate, and severe?
• How do environmental factors impact on the “atopic march”? 
Which factors will skew the immune system toward a proallergic/
T2 immune response?8
• Psychosocial factors may play a role in the development of allergic 
diseases.9 Do (psycho)social factors affect AD severity via psy-
choneuroimmunologic or behavioral pathways?
In a joint academic effort to address these gaps, a unique pa-
tient-centric project was started with the support of the Kühne 
Foundation: The CK-CARE registry and biobank program with 
currently more than 1200 patients recruited under real-world 
conditions.
The CK-CARE program aims (a) to explore the mechanisms un-
derlying the heterogeneity of AD and its various trajectories; (b) 
to identify and validate biomarkers of different values (diagnostic, 
prognostic, predictive, etc) for patient stratification in patient care, 
clinical trials, and research projects10; (c) to identify new potential 
drug targets; (d) to collect and learn from real-world data; and (e) to 
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction 
in any medium, provided the original work is properly cited and is not used for commercial purposes.
© 2020 The Authors. Allergy published by John Wiley & Sons Ltd
2  |     LETTER TO THE EDITOR
develop and provide tools for drug development programs in the era 
of precision medicine.
The CK-CARE program combines several crucial features (see 
Figure 1):
• The diversity of recruited patients: from newborns to very old pa-
tients with active AD of any severity or in remission. As controls, 
following population will also be included: nonatopic individuals 
(based on personal family history) (n = 200), atopic individuals 
with asthma and/or rhinitis but never had AD (n = 100); patients 
suffering from psoriasis (n = 100) and patients with “dormant AD” 
(as defined above) (n = 100).
• Detailed phenotypic information including severity scoring 
(SCORAD and EASI), atopy stigmata, patient-related outcomes, 
comorbidities, psychosocial aspects, etc.
• A comprehensive collection of epidemiological data including de-
tailed information on the family history, the course of the disease, 
diet habits, current and past therapies, etc.
• Collection of biomaterials including swabs for microbiomics, 
serum samples, peripheral blood cells, genomic DNA, and skin 
biopsies.
• All the biomaterials are stored in duplicate at the recruitment site 
and at the central biobank facility (CK-CARE headquarter at the 
campus in Davos, Switzerland).
• Photographic documentation.
• The patients are followed with one visit per year for at least 
5 years.
Based on this platform, the CK-CARE research program will be 
able to address many important gaps, some of them being listed 
below:
• Its birth cohort will provide in-depth information on the individual 
trajectories of AD, their immunological kinetics, the emergence of 
comorbidities. The identification of a window of opportunity for 
prevention and therapeutic interventions in high-risk populations 
defined by biomarkers.
• The follow-up approach will enable us to explore the immune re-
sponse and the skin microbiome in different age ranges as well as 
during childhood when the remission phase is expected to occur.
• Individuals in long-term remission will deliver insight into the im-
munologic status in this phase.
• The reactivation of AD in older patients (concept of “dormant dis-
ease”) and the role of environmental factors will be explored in a 
retrospective and prospective manner.
• The inclusion of patients with late/very late onset provides crucial 
insights in this ill-defined phenotype and helps to define pheno-
type- and endotype-based diagnostic criteria for older patients.
F I G U R E  1   Schematic representation of the information and materials collected by the CK-CARE program in the consortium centers in 
Bonn and Augsburg (Germany), in Zürich, St. Gallen and medical campus in Davos (Switzerland). About 1000 data points on epidemiologic 
and phenotypic information are collected per patient at each visit. The follow-up study is planned for at least 5 y. All procedures are codified 
according to SOP and subjected to quality control
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• The immunological analysis of the late/very late onset or reactiva-
tion will provide key information on the potential role of systemic 
inflammation in the emergence of atopic/nonatopic comorbidities 
and the benefit of targeted therapies in a biomarker-based strati-
fication of AD patients.
We are far from understanding the mechanistic complexity of 
the AD puzzle. With the analysis of comprehensive sets of patient 
information and biomaterial, the CK-CARE program will contribute 
to the discovery and validation of relevant biomarkers and pave the 
way to precision medicine in AD.
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